Lupin’s Nagpur Unit-1 gets FDA nod with VAI status

Global pharmaceutical powerhouse, Lupin Limited has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Nagpur Unit-1 manufacturing facility, specializing in oral solid dosage forms. This significant milestone follows the facility’s latest inspection in July 2023, with the U.S. FDA granting it a Voluntary Action Indicated (VAI) classification.

Nilesh Gupta, Managing Director of Lupin, expressed delight, stating, “We are pleased to receive the EIR with a VAI status from the U.S. FDA for the recent inspection of our Nagpur Unit-1 facility. This achievement underscores our commitment to quality and compliance and also mirrors our core values, reaffirming our commitment to providing high-quality healthcare solutions to our patients around the world.”